UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________

FORM 8-K

___________

CURRENT REPORT

Pursuant To Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~December~~March 0407, ~~2017~~2018

FUTURELAND CORP.
(Exact name of registrant as specified in charter)

Colorado	000-53377	41-2230041
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

FutureLand Corp. 10901 Roosevelt Blvd, 1000c Saint Petersburg, Florida		33716
(Address of principal executive offices)		(Zip Code)

(727) 474-0221
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

FORWARD LOOKING STATEMENTS

This Form 8-K and other reports filed by Registrant from time to time with the Securities and Exchange Commission (collectively the "Filings") contain or may contain forward looking statements and information that are based upon beliefs of, and information currently available to, Registrant's management as well as estimates and assumptions made by Registrant's management. When used in the filings the words "anticipate", "believe", "estimate", "expect", "future", "intend", "plan" or the negative of these terms and similar expressions as they relate to Registrant or Registrant's management identify forward looking statements. Such statements reflect the current view of Registrant with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to Registrant's industry, Registrant's operations and results of operations and any businesses that may be acquired by Registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

Although Registrant believes that the expectations reflected in the forward looking statements are reasonable, Registrant cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, Registrant does not intend to update any of the forward-looking statements to conform these statements to actual results.

Item 82.01 ~~Other~~Completion ~~Events~~of Acquisition or Disposition of Assets.

On ~~Nov.~~March 156, ~~2016 FutureLand Oregon~~2018, ~~LLC~~ ~~entered~~An ~~into~~Agreement anfor ~~agreement~~Plan ~~with HSPendleton, LLC and John C. Miller~~ of ~~Groovy~~Merger ~~Groves,~~(the ~~LLC. The company purchased 50% of 265~~“Agreement”) ~~acres~~was ~~in Wolf’s Creek, Oregon. The company also~~ entered ~~into~~by anCannabis ~~agreement to buy 50% ownership in Groovy Groves~~Leaf, ~~LLC by buying~~Inc. ~~out~~(“PCFP” ~~partner~~or ~~John~~“Cannabis C.Leaf”) ~~Miller~~a ~~for~~Nevada 10Corporation,~~000,000~~ ~~shares~~which ofis ~~FutureLand~~a ~~Corp’s~~publicly ~~common~~traded ~~stock.~~(OTC: ~~The~~PCFP), ~~deal~~1934 ~~was to be completed upon approval~~Securities ~~from~~Act ~~the~~reporting ~~OLCC~~company, onand ~~the~~Apotheca ~~transfer of license to FutureLand Oregon~~Biosciences, ~~LLC~~Inc. ~~from~~(hereafter ~~John~~referred C.to ~~Miller.~~as ~~The~~“ABI” ~~process~~or ~~has~~“Apotheca ~~taken longer than expected~~Biosciences”) ~~due~~a toNevada ~~many~~Corporation. ~~delays~~Such byAgreement ~~OLCC.~~will ~~But~~result ~~now~~in ~~all~~ the ~~requisite~~merger ~~paperwork~~of isApotheca ~~completed~~Biosciences ~~and~~into ~~submitted~~Cannabis ~~for~~Leaf, ~~final approval~~ with the ~~OLCC and~~Corporation weto ~~are~~survive ~~simply~~as ~~waiting~~Apotheca ~~on approval, which we believe is imminent~~Biosciences.

~~The~~FutureLand ~~harvest~~Corp ~~for Groovy Groves, LLC was nearly 400lbs this year and is currently being trimmed, dried, cured and~~ will goreceive ~~out for testing next month with sales expected to be made some time in January 2018. Although we expected quite a bit more product~~12, adjustments are being made to heavily increase yields for next year. Upon getting the transfer of license, Groovy Groves LLC will apply for a renewal that will include a plan to get a hybrid Tier 2 license with 5,000 ~~square feet of indoor and 20~~,000 ~~square~~shares ~~feet~~ of ~~outdoor.~~newly ~~This~~issued ~~will allow us to grow year-round.~~common ~~Ultimately,~~stock ~~everything may switch to indoor by the following year, but this is the current plan. With the way the laws are written right now we should be able to use the same footprint we currently have~~ for ~~the~~its 20~~,000~~% ~~square~~interest ~~feet of outdoor and at least double the number of plants we had this last year. Additionally, we should be able to get multiple harvests~~ in ~~the~~Apotheca ~~indoor facilities in the coming year and are prepared to make several modifications which should see 10X more product in 2018~~Biosciences.

~~SIGNATURES~~Apotheca Biosciences and Cannabis Leaf entered into the Merger Agreement where Cannabis Leaf agreed to deliver to Apotheca Biosciences a certain issuance of sixty million (60,000,000) common shares of Cannabis Leaf, Inc. (the “Exchange Shares”), in exchange for all shares of Apotheca Biosciences being acquired into Cannabis Leaf, which would result in a change in control of Cannabis Leaf with such issuance. The issuance will result in Apotheca Biosciences being the surviving company under the laws of the State of Nevada. Under the Agreement, upon closing, Apotheca Biosciences will receive the immediate right to appointment of the directors and officers of the surviving company by the resignation of the existing director and officer of Cannabis Leaf, with the simultaneous appointment of two directors and officers being appointed by Apotheca. The issuance of the 60,000,000 common shares of Cannabis Leaf will represent the controlling interest of Cannabis Leaf, Inc. after such merger occurs.

~~Pursuant~~Additionally, to the ~~requirements of~~Parties ~~the~~have ~~Securities~~agreed ~~Exchange~~to ~~Act~~change ~~of 1934,~~ the ~~Registrant~~name ~~has~~of ~~duly~~Cannabis Leaf, ~~caused~~Inc ~~this Report~~ to beApotheca ~~signed~~Biosciences, onInc. ~~its~~under ~~behalf~~Nevada ~~by the undersigned hereunto duly authorized~~law.

	FUTURELAND CORP.
Date: December 04 2017	By: /s/ Cameron Cox
	Cameron Cox, Principal Executive Officer

Apotheca Biosciences is developing cutting-edge medical products, nutraceuticals, formulation and delivery technologies for the healthcare and consumer care industry. Their pipeline of products includes, transdermal, sublingual, and nasal delivery technologies for precise and controlled dosing of cannabinoids.

Apotheca Biosciences is a pioneering biotech company with an emphasis in research and development in addition to the creation of high-grade nutraceuticals and cosmetics. Apothecia’s’ goal is to lay the groundwork and continue research of cannabinoid receptiveness in patients and create nutraceuticals that reflects their research.

More information on Apotheca Biosciences can be found at: http://www.apothecabiosciences.com/

The Parties project the formal closing for the transaction to occur on May 15, 2018, with the release block of control shares. The Company will file a combined audited financial statement under SEC guidelines.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

	FUTURELAND CORP.

Date: March 07, 2018	By: /s/ Cameron Cox
	Cameron Cox, Principal Executive Officer

Filing Compare · FUTURELAND CORP.